PURPOSE: Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND METHODS: We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score-weighted (PSW) analysis were performed. RESULTS: Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2). CONCLUSION: In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.
PURPOSE:Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND METHODS: We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015. The primary objective was to assess for improved progression-free survival (PFS) with AHCT consolidation and secondarily to assess for improved overall survival (OS). Cox multivariable regression analysis and propensity score-weighted (PSW) analysis were performed. RESULTS: Data were collected from 25 medical centers for 1,254 patients; 1,029 met inclusion criteria. Median follow-up for the cohort was 76 months. Median PFS and OS were 62 and 139 months, respectively. On unadjusted analysis, AHCT was associated with improved PFS (75 v 44 months with v without AHCT, respectively; P < .01) and OS (147 v 115 months with v without AHCT, respectively; P < .05). On multivariable regression analysis, AHCT was associated with improved PFS (hazard ratio [HR], 0.54; 95% CI, 0.44 to 0.66; P < .01) and a trend toward improved OS (HR, 0.77; 95% CI, 0.59 to 1.01; P = .06). After PSW analysis, AHCT remained associated with improved PFS (HR, 0.70; 95% CI, 0.59 to 0.84; P < .05) but not improved OS (HR, 0.87; 95% CI, 0.69 to 1.1; P = .2). CONCLUSION: In this large cohort of younger, transplantation-eligible patients with MCL, AHCT consolidation after induction was associated with significantly improved PFS but not OS after PSW analysis. Within the limitations of a retrospective analysis, our findings suggest that in younger, fit patients, AHCT consolidation may improve PFS.
Authors: Eva Hoster; Wolfram Klapper; Olivier Hermine; Hanneke C Kluin-Nelemans; Jan Walewski; Achiel van Hoof; Marek Trneny; Christian H Geisler; Francesco Di Raimondo; Michal Szymczyk; Stephan Stilgenbauer; Catherine Thieblemont; Michael Hallek; Roswitha Forstpointner; Christiane Pott; Vincent Ribrag; Jeanette Doorduijn; Wolfgang Hiddemann; Martin H Dreyling; Michael Unterhalt Journal: J Clin Oncol Date: 2014-03-31 Impact factor: 44.544
Authors: Eva Hoster; Andreas Rosenwald; Françoise Berger; Heinz-Wolfram Bernd; Sylvia Hartmann; Christoph Loddenkemper; Thomas F E Barth; Nicole Brousse; Stefano Pileri; Grzegorz Rymkiewicz; Roman Kodet; Stephan Stilgenbauer; Roswitha Forstpointner; Catherine Thieblemont; Michael Hallek; Bertrand Coiffier; Ursula Vehling-Kaiser; Réda Bouabdallah; Lothar Kanz; Michael Pfreundschuh; Christian Schmidt; Vincent Ribrag; Wolfgang Hiddemann; Michael Unterhalt; Johanna C Kluin-Nelemans; Olivier Hermine; Martin H Dreyling; Wolfram Klapper Journal: J Clin Oncol Date: 2016-02-29 Impact factor: 44.544
Authors: Jorge E Romaguera; Luis Fayad; Maria A Rodriguez; Kristine R Broglio; Frederick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth L Katz; Harish Gagneja; Barry I Samuels; Terry L Smith; Fernando F Cabanillas Journal: J Clin Oncol Date: 2005-09-06 Impact factor: 44.544
Authors: E Vandenberghe; C De Wolf-Peeters; G Vaughan Hudson; B Vaughan Hudson; S Pittaluga; L Anderson; D C Linch Journal: Br J Haematol Date: 1997-12 Impact factor: 6.998
Authors: Alexandra Smith; Simon Crouch; Debra Howell; Cathy Burton; Russell Patmore; Eve Roman Journal: Cancer Epidemiol Date: 2015-09-02 Impact factor: 2.984
Authors: Ingrid Glimelius; Karin E Smedby; Alexandra Albertsson-Lindblad; Michael J Crowther; Sandra Eloranta; Mats Jerkeman; Caroline E Weibull Journal: Blood Adv Date: 2021-03-23
Authors: Peter A Riedell; Mehdi Hamadani; Kwang W Ahn; Carlos Litovich; Guru Subramanian Guru Murthy; Frederick L Locke; Claudio G Brunstein; Reid W Merryman; Patrick J Stiff; Attaphol Pawarode; Taiga Nishihori; Mohamed A Kharfan-Dabaja; Alex F Herrera; Craig S Sauter; Sonali M Smith Journal: Transplant Cell Ther Date: 2021-08-24
Authors: Diego Villa; Laurie H Sehn; Kerry J Savage; Cynthia L Toze; Kevin Song; Wendie D den Brok; Ciara L Freeman; David W Scott; Alina S Gerrie Journal: Blood Adv Date: 2020-08-11
Authors: Krithika Shanmugasundaram; Subir Goyal; Jeffery Switchenko; Oscar Calzada; Michael C Churnetski; Bhaskar Kolla; Veronika Bachanova; James N Gerson; Stefan K Barta; Max J Gordon; Alexey V Danilov; Natalie S Grover; Stephanie Mathews; Madelyn Burkart; Reem Karmali; Yazeed Sawalha; Brian T Hill; Nilanjan Ghosh; Steven I Park; Narendranath Epperla; David A Bond; Talha Badar; Kristie A Blum; Mehdi Hamadani; Timothy S Fenske; Mary Malecek; Brad S Kahl; Peter Martin; Jin Guo; Christopher R Flowers; Jonathon B Cohen Journal: Eur J Haematol Date: 2021-06-17 Impact factor: 2.997
Authors: Reem Karmali; Jeffrey M Switchenko; Subir Goyal; Krithika Shanmugasundaram; Michael C Churnetski; Bhaskar Kolla; Veronika Bachanova; James N Gerson; Stefan K Barta; Max J Gordon; Alexey V Danilov; Natalie S Grover; Narendranath Epperla; Stephanie Mathews; Madelyn Burkart; Yazeed Sawalha; Brian T Hill; Nilanjan Ghosh; Steven I Park; David A Bond; Kami J Maddocks; Talha Badar; Timothy S Fenske; Mehdi Hamadani; Jin Guo; Mary Malecek; Brad S Kahl; Peter Martin; Kristie A Blum; Christopher R Flowers; Jonathon B Cohen Journal: Am J Hematol Date: 2021-08-10 Impact factor: 10.047